All In Biotech

NDA 011909 · Parke Davis

Nardil

Phenelzine Sulfate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Aug 2, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1961

Jun 9, 1961

Approved uses

1

Original approval plus efficacy supplements

Registered trials

11

0 Phase 3, 0 recruiting

FAERS reports

1,575

904 serious, 41 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Nardil or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for...

What it is approved for

From the label in effect Nov 5, 2026.

INDICATIONS AND USAGE NARDIL has been found to be effective in depressed patients clinically characterized as "atypical," "nonendogenous," or "neurotic." These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. NARDIL should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 9, 1961 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • NARDIL · PHENELZINE SULFATE EQ 15MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Phenelzine" as an intervention, any sponsor and status, largest first.

All 11 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective330
  • depression187
  • headache138
  • anxiety129
  • weight increased122
  • insomnia104
  • dizziness100
  • drug interaction100
  • pharmaceutical product complaint97
  • fatigue94
  • feeling abnormal89
  • malaise78

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004106
200586
200653
200753
200850
200940
2010187
201188
201298
201359
201465
201591
201657
201766
201868
201942
2020121
202195
202227
202342
202439
202519
202623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nardil (Phenelzine Sulfate)

2024 spending

$107K

Beneficiaries

52

235 claims

Per beneficiary

$2,066

$2.44 per unit

View as table
YearSpending
2020$276,138
2021$103,708
2022$130,721
2023$116,313
2024$107,431

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 189 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.